Cannabinoids in the Treatment of Epilepsy.

The pharmacologic and biochemical features of cannabinoids make them candidates for antiseizure medications. At this time, anecdotes have outstripped controlled clinical trials as sources of support for their clinical value.

[1]  Benjamin J. Whalley,et al.  Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. , 2014, ACS chemical neuroscience.

[2]  P. Consroe,et al.  Anticonvulsant nature of marihuana smoking. , 1975, JAMA.

[3]  K. Knupp,et al.  Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy , 2015, Epilepsy & Behavior.

[4]  Nora D Volkow,et al.  Adverse health effects of marijuana use. , 2014, The New England journal of medicine.

[5]  J. Axelrod,et al.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Behnke,et al.  Prenatal Substance Abuse: Short- and Long-term Effects on the Exposed Fetus , 2013, Pediatrics.

[7]  B. Vickrey,et al.  Cannabinoids for epilepsy. , 2014, The Cochrane database of systematic reviews.

[8]  Sylvain Rheims,et al.  Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy , 2008, PLoS medicine.

[9]  F. Guimarães,et al.  Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. , 2012, Journal of psychiatric research.

[10]  Manjit,et al.  Neurology , 1912, NeuroImage.

[11]  E. Carlini,et al.  Chronic administration of cannabidiol to healthy volunteers and epileptic patients. , 1980, Pharmacology.

[12]  M. Marciani,et al.  Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy , 2010, Epilepsia.

[13]  N. Cimino,et al.  Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review , 2014, Drug metabolism reviews.

[14]  J D Norrie,et al.  Patterns of treatment response in newly diagnosed epilepsy , 2012, Neurology.

[15]  P. Enck,et al.  Placebo effects in children: a review , 2013, Pediatric Research.

[16]  S. Macleod,et al.  Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. , 1987, Pediatrics.

[17]  P. Garcia,et al.  Seizure exacerbation in two patients with focal epilepsy following marijuana cessation , 2012, Epilepsy & Behavior.

[18]  B. Bahr,et al.  Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage , 2007, Journal of Pharmacology and Experimental Therapeutics.

[19]  C. Hillard,et al.  Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Sellers,et al.  A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use , 2011, Human psychopharmacology.

[21]  O. Devinsky.  Commentary: Medical Marijuana Survey & Epilepsy , 2015, Epilepsia.

[22]  Benjamin J. Whalley,et al.  Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism , 2013, British journal of pharmacology.

[23]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs , 2003, The Lancet Neurology.

[24]  M. Cascio,et al.  Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids , 2014 .

[25]  R. Greenwood,et al.  Adverse Effects of Antiepileptic Drugs , 2000, Epilepsia.

[26]  J. Brust,et al.  Marijuana use and the risk of new onset seizures. , 1992, Transactions of the American Clinical and Climatological Association.

[27]  Beat Lutz,et al.  The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus , 2006, Neuron.

[28]  M. Cascio,et al.  Known Pharmacological Actions of Delta-9-Tetrahydrocannabinol and of Four Other Chemical Constituents of Cannabis that Activate Cannabinoid Receptors , 2014 .

[29]  A. Thompson,et al.  Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  B. Martin,et al.  The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[31]  Masahiko Watanabe,et al.  Downregulation of the CB1 Cannabinoid Receptor and Related Molecular Elements of the Endocannabinoid System in Epileptic Human Hippocampus , 2008, The Journal of Neuroscience.

[32]  B. Porter,et al.  Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy , 2013, Epilepsy & Behavior.

[33]  Andrew J. Hill,et al.  The Development of Cannabinoid Based Therapies for Epilepsy , 2013 .

[34]  J. Bronstein,et al.  Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders , 2014, Neurology.

[35]  D. M. Feeney.  Marihuana Use Among Epileptics , 1976 .

[36]  Benjamin J. Whalley,et al.  Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.

[37]  D. Rusakov,et al.  Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses , 2013, Proceedings of the National Academy of Sciences.

[38]  M. Holtkamp,et al.  Cannabis and other illicit drug use in epilepsy patients , 2014, European journal of neurology.

[39]  R. Pertwee.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.

[40]  M. Yücel,et al.  Gross morphological brain changes with chronic, heavy cannabis use. , 2015, The British journal of psychiatry : the journal of mental science.

[41]  B. Trumbly.  Double-blind clinical study of cannabidiol as a secondary anticonvulsant , 1990 .

[42]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[43]  M. Keeler,et al.  Grand mal convulsions subsequent to marijuana use. Case report. , 1967, Diseases of the nervous system.

[44]  D. Gross,et al.  Marijuana use and epilepsy , 2004, Neurology.

[45]  R. Pertwee.  The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin , 2007 .

[46]  Richie Poulton,et al.  Persistent cannabis users show neuropsychological decline from childhood to midlife , 2012, Proceedings of the National Academy of Sciences.

[47]  O. Røgeberg.  Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status , 2013, Proceedings of the National Academy of Sciences.

[48]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[49]  O. Devinsky,et al.  Alcohol and Marijuana: Effects on Epilepsy and Use by Patients with Epilepsy , 2001, Epilepsia.

[50]  G. Sharma,et al.  Constituents of Cannabis sativa , 1979 .

[51]  Wayne Hall,et al.  Adverse effects of cannabis , 1998, The Lancet.

[52]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[53]  P. Robson.  Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine , 2011, Expert opinion on drug safety.

[54]  B. Tofighi,et al.  Internet Highs—Seizures After Consumption of Synthetic Cannabinoids Purchased Online , 2012, Journal of addiction medicine.

[55]  G. Mathern,et al.  Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: Result of Epilepsia's survey , 2015, Epilepsia.

[56]  J. Ellison,et al.  Complex partial seizure symptoms affected by marijuana abuse. , 1990, The Journal of clinical psychiatry.

[57]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[58]  J. Conry,et al.  Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome , 2011, Neurology.

[59]  C. Grady,et al.  Clinical Trials and Medical Care: Defining the Therapeutic Misconception , 2007, PLoS medicine.

[60]  P. Castillo,et al.  Endocannabinoid Signaling and Synaptic Function , 2012, Neuron.

[61]  T. Bisogno,et al.  Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.

[62]  S. Sombati,et al.  Endocannabinoids block status epilepticus in cultured hippocampal neurons. , 2007, European journal of pharmacology.

[63]  S. Sombati,et al.  Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy , 2007, Neuroscience Letters.

[64]  C. Collin,et al.  Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European journal of neurology.

[65]  O. Devinsky,et al.  Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. , 2007, Reviews in neurological diseases.

[66]  J. Killestein.  Cannabinoids in the Treatment of Epilepsy. , 2016, The New England journal of medicine.

[67]  R. Mechoulam,et al.  Toward drugs derived from cannabis , 2004, Naturwissenschaften.

[68]  J. Crippa,et al.  Safety and side effects of cannabidiol, a Cannabis sativa constituent. , 2011, Current drug safety.

[69]  M. Klugmann,et al.  AAV Vector-Mediated Overexpression of CB1 Cannabinoid Receptor in Pyramidal Neurons of the Hippocampus Protects against Seizure-Induced Excitoxicity , 2010, PloS one.

[70]  K. Heard,et al.  Pediatric marijuana exposures in a medical marijuana state. , 2013, JAMA pediatrics.

[71]  P. Novotny,et al.  Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  E. Maa,et al.  The case for medical marijuana in epilepsy , 2014, Epilepsia.

[73]  Keeler Mh,et al.  Grand mal convulsions subsequent to marijuana use. Case report. , 1967 .

[74]  F. Ames,et al.  Anticonvulsant effect of cannabidiol. , 1986, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.